FDA will not fire staff pending Congress' move
This article was originally published in Clinica
As the US Congress left last week for its month-long recess without passing a major Food and Drug Administration reform bill, FDA Commissioner Andrew von Eschenbach vowed that the FDA would use reserve funds rather than layoff employees. House and Senate leaders could not agree on a reform bill, which contains numerous post-market safety changes as well as reauthorisation for medical device and drug user fee programmes, and so the law requires the agency FDA to begin sending "reduction in force" notices to employees paid by those programmes.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.